Brind.
  1. Sana Biotechnology reported financial results and received FDA feedback on its IND filing.

Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.

1 report, 1 independent Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.

Who's involved

What this event is mainly about
Sana BiotechnologyFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Per-Ola Carlsson is appointed as the study principal investigator for Sana Biotechnology's ongoing treatments.Sub-event
  2. Sana Biotechnology delivered encouraging six-month data on its allogeneic CAR-T platform for Type 1 diabetes.Sub-event
  3. Sana is moving forward with GMP Master Cell Bank and conducting trials for its IND application.1 source

Keep exploring

Part of

Sana Biotechnology reported financial results and received FDA feedback on its IND filing. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireSana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Isl